Veltassa Powder, For Suspension
Product Images NDC 53436-252

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Veltassa (NDC 53436-252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vifor Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Veltassa 01)

Chemical structure diagram of patiromer sorbitex calcium, the active ingredient in VELTASSA, showing calcium-sorbitol counterion and patiromer anion polymeric network with associated water and variable crosslinking groups.*

FDA Label Image

Figure 2 (Veltassa 02)

A chart titled 'Geometric Mean Ratio and 90% CIs' displaying pharmacokinetic data (AUC and Cmax) for various reference drugs under two conditions: 'No Separation' and '3-Hour Separation.' The x-axis represents change relative to the reference drug, ranging from 0 to 1.5. Drugs listed include amlodipine, cinacalcet, ciprofloxacin, clopidogrel, furosemide, levothyroxine, lithium, metformin, metoprolol, trimethoprim, verapamil, and two forms of warfarin (R and S). Data points are shown as solid and open circles with horizontal confidence intervals.*

FDA Label Image

Figure 3 (Veltassa 03)

A line graph showing mean serum potassium levels (mEq/L) with 95% confidence intervals across different study visits from baseline to week 4. The graph compares potassium levels for two baseline groups (5.1 to <5.5 mEq/L and 5.5 to <6.5 mEq/L) and the total population, illustrating a decrease in serum potassium over time.*

FDA Label Image

Figure 4 (Veltassa 04)

A line graph depicting mean serum potassium levels (mEq/L) over weeks of a study, with two groups based on baseline serum potassium stratification: 5.0 to 5.5 mEq/L (dashed line) and 5.5 to 6.0 mEq/L (solid line). The x-axis represents study weeks with a follow-up period, and the y-axis shows serum potassium levels with error bars indicating 95% confidence intervals. Subject numbers per time point are listed below the x-axis.*

FDA Label Image

Principal Display Panel (8.4 g Packet Carton)

Veltassa (patiromer) 8.4 g powder for suspension carton, containing 30 packets. The purple and white packaging includes the Veltassa logo and indicates it is for oral suspension. The label states each packet contains 8.4 grams of patiromer and xanthan gum, with storage and usage instructions. Manufactured by Vifor Pharma, Inc., Redwood City, CA.*

FDA Label Image

Principal Display Panel (16.8 g Packet Carton)

Packaging label for Veltassa (patiromer) 16.8 g powder for oral suspension from Vifor Pharma, Inc. The carton indicates 30 packets per box with each packet containing 16.8 grams of patiromer. Directions for use and storage instructions are printed, including mixing with water and refrigeration guidance. Manufactured in Canada.*

FDA Label Image

Principal Display Panel (25.2 g Packet Carton)

Packaging label for VELTASSA (patiromer) powder for oral suspension, 25.2 g strength, supplied in 30 packets. The box is labeled with dosing information and manufacturer details for Vifor Pharma, Inc. The design includes purple and green text on a white and gray background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.